Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2003

View Archived Issues

CAT, Micromet and Enzon sign crosslicense agreement

Reduced mortality associated with pexelizumab in acute myocardial infarction

ALT-711 improves diastolic filling and quality of life in patients with DHF

Ranolazine equally safe and effective in diabetic and nondiabetic patients with angina

Good efficacy and safety profiles described for ivabradine and atenolol in stable angina

Elidel studies reveal patient satisfaction with eczema treatment

Two new phase I trials investigate Xcytrin plus Taxotere for advanced cancers

Provenge receives fast track designation

Phase I trial evaluates safety of AMD-070 for treatment of HIV infection

Theratechnologies signs agreement for use of ExoPep platform

Merck claims new S1P1 receptor agonists with potential as immunosuppressants

New anti-HCV agents in early development at Ribapharm

Toa Eiyo scientists prepare and test novel glucose- and lipid-lowering agents

Dual sigma receptor ligands/AChE inhibitors and their use in psychosis, dementia, etc.

Kyorin patent covers new NK1 antagonists for urinary incontinence and other uses

Micromet to develop CAT's EpCAM-targeting antibody

Microbicide UC-781 enters phase I

Pozen and Xcel sign commercialization agreement for MT-300

Selective anti-H. pylori agent synthesized in China

Positive preclinical results indicate utility of AVI-4179 for treatment of SARS

Promising anti-HIV agent targets HIV-1 envelope protein

Japanese group identifies new antiangiogenic/antimetastatic MMP inhibitor

Continued development of QR-337 to be conducted under IND

Milestone in Vicuron and Novartis peptide deformylase inhibitor collaboration

Bicyclic androgen receptor antagonists pursued at BMS

GW-572016, a dual EGFR/ErbB-2 TK inhibitor, discussed in ACS presentation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...